NEW YORK--(BUSINESS WIRE)--
Retrophin, Inc. (NASDAQ:RTRX) today announced that the Board of
Directors has appointed Stephen Aselage as Chief Executive Officer
(CEO), effective immediately. Mr. Aselage has been serving as the
company's interim CEO since September 30, 2014.
"Steve has done an excellent job of guiding Retrophin through a period
of significant change," said Steve Richardson, Chairman of the Board of
Directors. "He has demonstrated compelling leadership and vision while
working with the Board and management team to develop a plan that
maximizes our commercial capabilities and focuses development efforts on
assets with the highest potential returns. The Board is delighted that
Steve has agreed to continue to lead Retrophin and execute our newly
focused strategic plan."
"I am honored to have the opportunity to continue working with the
talented team at Retrophin as we bring life-changing treatments to our
patients and value to our shareholders," said Mr. Aselage. "I've gained
a tremendous appreciation for our exceptional R&D capabilities,
commercial talent, and highly effective business development efforts,
all of which position Retrophin for continued success."
Mr. Aselage has more than 30 years of pharmaceutical and biotechnology
experience. Most recently, he was Executive Vice President and Chief
Business Officer of BioMarin Pharmaceutical Inc. During his seven years
with BioMarin, he built the commercial and medical affairs functions
that launched three commercial products and developed commercial
businesses in more than 45 countries. Mr. Aselage has also held
leadership roles with Cell Therapeutics, Sangstat Medical Corporation,
Advanced Tissue Sciences, and Genentech. He worked briefly for Genzyme
as well, assisting in the transition following its acquisition of
Sangstat. Earlier in his career, he held a variety of sales and sales
management positions at companies including Rhone-Poulenc Rorer
Pharmaceuticals (now Sanofi-Aventis) and Bristol Laboratories. Mr.
Aselage received his B.S. in Biology from the University of Notre Dame.
About Retrophin
Retrophin is a pharmaceutical company focused on the development,
acquisition and commercialization of drugs for the treatment of serious,
catastrophic or rare diseases for which there are currently no viable
options for patients. The Company's approved products include Chenodal®,
Thiola® and Vecamyl®, and its pipeline includes compounds for several
catastrophic diseases, including focal segmental glomerulosclerosis
(FSGS), pantothenate kinase-associated neurodegeneration (PKAN),
schizophrenia, infantile spasms, nephrotic syndrome and others. For
additional information, please visit www.retrophin.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995,
regarding the research, development and commercialization of
pharmaceutical products. Without limiting the foregoing, these
statements are often identified by the words "may", "might", "believes",
"thinks", "anticipates", "plans", "expects", "intends" or similar
expressions. No forward-looking statement can be guaranteed. You are
cautioned not to place undue reliance on these forward-looking
statements as there are important factors that could cause actual
results to differ materially from those in forward-looking statements,
many of which are beyond our control. The Company undertakes no
obligation to publicly update forward-looking statements, whether as a
result of new information, future events, or otherwise. Investors are
referred to the full discussion of risks and uncertainties as included
in the Company's filings with the Securities and Exchange Commission.
Retrophin, Inc.
Marc Panoff, 646-564-3671
CFO
marc@retrophin.com
or
Chris
Cline, CFA, 646-564-3680
Manager, Investor Relations
IR@retrophin.com
Source: Retrophin, Inc.
News Provided by Acquire Media